International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  • End date
    Jan 2, 2029
  • participants needed
  • sponsor
    Prostate Cancer Clinical Trials Consortium
Updated on 2 September 2021
castration-resistant prostate cancer


Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Brazil, Canada, Ireland, Sweden, Switzerland, the United Kingdom (UK), and the US. Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.

Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of three years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.

PROMs questionnaires will be collected at enrollment, every three months for the first and second year then every six months.

Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.

As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.

Condition Malignant neoplasm of prostate, Prostatic disorder, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment Standard of Care
Clinical Study IdentifierNCT03151629
SponsorProstate Cancer Clinical Trials Consortium
Last Modified on2 September 2021


Yes No Not Sure

Inclusion Criteria

Males of any race between 35 and 55 years of age
Body mass index between 18.0 and 30.0 kg/m2
In good health
Males will agree to use contraception
Able to comprehend and sign an informed consent form
History of a minimum of 1 bowel movement per day

Exclusion Criteria

History of significant medical illness
History of clinically significant drug allergy
History of a seizure disorder, not including infantile seizures
History of stomach or intestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs
Clinically significant medical treatment within 8 weeks or infection treatment within 4 weeks of dosing
Clinically significant ECG abnormality
History of alcoholism or drug/chemical abuse within the previous 2 years or positive screening test
Significant alcohol consumption
Positive hepatitis panel and/or positive human immunodeficiency virus test
Use of prohibited prescription, over-the-counter medications or natural health products
Use of tobacco or nicotine-containing products within 3 months prior to Check-in or positive screening test
Receipt of blood products within 2 months prior to Check in
Recent donation of blood, plasma, or platelets prior to Screening
Exposure to significant diagnostic, therapeutic or employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in
Evidence or history of active suicidal thoughts in the previous 5 years or have any lifetime history of a suicide attempt
Not suitable for study in the opinion of the Principal Investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note